← Feed

Sukhtian Ghiath M.

SEC Form 4 insider
Outlook Therapeutics, Inc. ($OTLK)
1 thesis · first seen Aug 15, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$OTLKSEC Form 4bullish
Sukhtian Ghiath M. · Outlook Therapeutics, Inc. · 3h agono track record yet
Long 2,525,252 shares of OTLK
Bought 2,525,252 @ $0.99 avg · $2,499,999 · 2026-08-12

Form 4: Sukhtian Ghiath M. bought OTLK

Sukhtian Ghiath M. (Director at Outlook Therapeutics, Inc.) reported an open-market purchase of 2,525,252 shares of OTLK at an average $0.99, roughly $2,499,999, in a Form 4 filed 2026-08-14.

View filing on SEC.gov →

End of results.